• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    8/17/23 9:06:07 AM ET
    $ACON
    $AHI
    $CALT
    $INFI
    Medical Specialities
    Health Care
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $ACON alert in real time by email

    Gainers

    • Tivic Health Systems (NASDAQ:TIVC) stock increased by 47.2% to $0.1 during Thursday's pre-market session. The company's market cap stands at $14.4 million. As per the news, the Q2 earnings report came out 3 days ago.
    • Advanced Health (NASDAQ:AHI) shares rose 31.51% to $5.05. The company's market cap stands at $35.3 million.
    • Pliant Therapeutics (NASDAQ:PLRX) shares increased by 31.15% to $22.56. The market value of their outstanding shares is at $1.3 billion.
    • Modular Medical (NASDAQ:MODD) shares increased by 28.58% to $1.26. The company's market cap stands at $26.5 million. As per the news, the Q1 earnings report came out 3 days ago.
    • Infinity Pharmaceuticals (NASDAQ:INFI) shares rose 16.54% to $0.13. The market value of their outstanding shares is at $11.6 million.
    • Shuttle Pharmaceuticals (NASDAQ:SHPH) shares increased by 14.82% to $0.91. The market value of their outstanding shares is at $12.5 million.

    Losers

    • T2 Biosystems (NASDAQ:TTOO) stock fell 24.4% to $0.43 during Thursday's pre-market session. The market value of their outstanding shares is at $143.4 million.
    • Novo Integrated Sciences (NASDAQ:NVOS) shares fell 19.11% to $0.15. The market value of their outstanding shares is at $21.7 million.
    • Strata Skin Sciences (NASDAQ:SSKN) stock declined by 12.94% to $0.51. The market value of their outstanding shares is at $17.6 million.
    • Kronos Bio (NASDAQ:KRON) stock decreased by 12.43% to $1.41. The market value of their outstanding shares is at $82.2 million.
    • Calliditas Therapeutics (NASDAQ:CALT) stock decreased by 12.25% to $16.63. The company's market cap stands at $446.2 million. As per the press release, Q2 earnings came out today.
    • Aclarion (NASDAQ:ACON) stock fell 9.57% to $0.44. The company's market cap stands at $3.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON
    $AHI
    $CALT
    $INFI

    CompanyDatePrice TargetRatingAnalyst
    Pliant Therapeutics Inc.
    $PLRX
    10/10/2025Neutral → Underweight
    Analyst
    Pliant Therapeutics Inc.
    $PLRX
    3/4/2025Buy → Hold
    Needham
    Pliant Therapeutics Inc.
    $PLRX
    3/4/2025Neutral
    Cantor Fitzgerald
    Pliant Therapeutics Inc.
    $PLRX
    3/3/2025Buy → Hold
    Stifel
    Pliant Therapeutics Inc.
    $PLRX
    3/3/2025Outperform → Market Perform
    Leerink Partners
    Pliant Therapeutics Inc.
    $PLRX
    2/10/2025Overweight → Neutral
    Analyst
    Pliant Therapeutics Inc.
    $PLRX
    2/10/2025$43.00 → $4.00Buy → Hold
    Canaccord Genuity
    Pliant Therapeutics Inc.
    $PLRX
    2/10/2025Outperform → Perform
    Oppenheimer
    More analyst ratings

    $ACON
    $AHI
    $CALT
    $INFI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Ness Brent bought $62 worth of shares (10 units at $6.20), increasing direct ownership by 1,000% to 11 units (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    12/1/25 5:00:02 PM ET
    $ACON
    Medical Specialities
    Health Care

    Director Rubinstein Samuel sold $18,804 worth of shares (14,094 units at $1.33) and bought $7,028 worth of shares (5,000 units at $1.41), decreasing direct ownership by 51% to 8,766 units (SEC Form 4)

    4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

    11/18/25 4:35:42 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Manchester Management Co Llc bought $1,299,997 worth of shares (677,082 units at $1.92) (SEC Form 4)

    4 - Modular Medical, Inc. (0001074871) (Issuer)

    3/24/25 9:34:00 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    $ACON
    $AHI
    $CALT
    $INFI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TARPEYO issued to CALLIDITAS THERAPEUTICS AB

    Submission status for CALLIDITAS THERAPEUTICS AB's drug TARPEYO (ORIG-1) with active ingredient BUDESONIDE has changed to 'Approval' on 12/15/2021. Application Category: NDA, Application Number: 215935, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/20/21 3:40:41 PM ET
    $CALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $AHI
    $CALT
    $INFI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ACON
    $AHI
    $CALT
    $INFI
    SEC Filings

    View All

    Chief Operating Officer Handley Michael K converted options into 8,824 shares (SEC Form 4)

    4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

    2/20/26 4:19:42 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Chief Financial Officer Cummings Keith Lamont

    4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)

    1/26/26 4:36:53 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Operating Officer Kuo Minnie

    4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)

    1/26/26 4:36:47 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Strata Skin Sciences Inc.

    EFFECT - STRATA Skin Sciences, Inc. (0001051514) (Filer)

    3/5/26 12:15:03 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Strata Skin Sciences Inc.

    EFFECT - STRATA Skin Sciences, Inc. (0001051514) (Filer)

    3/5/26 12:15:07 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Strata Skin Sciences Inc.

    EFFECT - STRATA Skin Sciences, Inc. (0001051514) (Filer)

    3/5/26 12:15:06 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    $ACON
    $AHI
    $CALT
    $INFI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Pliant Therapeutics downgraded by Analyst

    Analyst downgraded Pliant Therapeutics from Neutral to Underweight

    10/10/25 8:29:23 AM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pliant Therapeutics downgraded by Needham

    Needham downgraded Pliant Therapeutics from Buy to Hold

    3/4/25 8:19:24 AM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Pliant Therapeutics

    Cantor Fitzgerald resumed coverage of Pliant Therapeutics with a rating of Neutral

    3/4/25 7:42:23 AM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $AHI
    $CALT
    $INFI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference

    SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference being held in a virtual format February 25-26, 2026. Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer and Keith Cummings, M.D., Chief Financial Officer, will participate in a fireside chat on Wednesday, February 25, 2026, at 2:40 p.m. Eastern Time. Interested parties may access the live webcast of the fireside chat by visiting here or the Investor Relations' Ev

    2/23/26 8:00:00 AM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    STRATA Skin Sciences Confirms Nasdaq Delisting

    HORSHAM, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that a Form 25 has been filed today with the SEC to deregister its common stock under Section 12(b) of the Securities Exchange Act of 1934, as amended ("Exchange Act"), and confirms that trading of the Company's common stock has been suspended from trading on The Nasdaq Capital Market ("Nasdaq") at the opening of business on February 19, 2026. The Company also expects to file a Form 15 with the SEC on or about March

    2/19/26 4:05:00 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    Johns Hopkins Dermatology Expands Advanced Care for Inflammatory and Autoimmune Skin Conditions with Addition of XTRAC® Excimer Laser

    HORSHAM, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative dermatologic treatments, today announces that Johns Hopkins Dermatology has added the XTRAC® 308 nm excimer laser to its clinical treatment offerings. The addition of XTRAC enhances Johns Hopkins' ability to deliver advanced, targeted care for patients living with chronic inflammatory and autoimmune skin diseases, including psoriasis, vitiligo, atopic dermatitis, and other complex dermatologic conditions. The technology will also support ongoing clinical research and academic initiatives within the departm

    2/18/26 8:15:00 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    $ACON
    $AHI
    $CALT
    $INFI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Modular Medical Inc.

    SC 13D/A - Modular Medical, Inc. (0001074871) (Subject)

    11/25/24 7:18:33 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Pliant Therapeutics Inc.

    SC 13G - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

    11/14/24 9:00:58 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Pliant Therapeutics Inc.

    SC 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

    11/14/24 5:05:23 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $AHI
    $CALT
    $INFI
    Leadership Updates

    Live Leadership Updates

    View All

    Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

    Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companiesStrong track record of launching breakthrough technologies across spine, neurosurgery and pain managementStrengthens Aclarion's commercial execution as the Company expands adoption and payer engagement across the Eastern U.S. BROOMFIELD, Colo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the

    12/2/25 8:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Shuttle Pharmaceuticals Acquires AI Health Platform

    Rockville, Maryland--(Newsfile Corp. - November 21, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle" or the "Company") today announced that it has closed the acquisition of the assets and liabilities of 1542770 B.C. Ltd. d/b/a Molecule.ai ("Molecule"), a Canadian artificial intelligence company specializing in molecular discovery and drug development technologies.Under the terms of the agreement, 1563868 B.C. Ltd., a wholly owned subsidiary of Shuttle, acquired substantially all of Molecule's assets and liabilities for a total purchase price of $8 million, payable in a combination of cash and shares of Shuttle common stock, plus an additional contingent $2 million, pay

    11/21/25 9:30:00 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

    Marks Aclarion's first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgeryExperiencing strong commercial traction in UK as first market worldwide with private insurers covering NociscanNociscan reimbursed by three of top four private insurers in UK, giving access to more than 5.2 million covered lives BROOMFIELD, Colo., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announc

    11/5/25 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    $AHI
    $CALT
    $INFI
    Financials

    Live finance-specific insights

    View All

    Tivic Health to Report Third Quarter 2025 Financial Results on November 14th Via Conference Call and Webcast

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that it will report its third quarter results for 2025 via pre-recorded conference call and webcast on Friday, November 14, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 230582 Webcast Link https://www.webcaster5.com/Webcast/Page/2865/53145 About Tivic Health Systems, Inc. Tivic's dual platform utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell

    11/6/25 9:30:00 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    STRATA Skin Sciences to Report Third Quarter 2025 Financial Results on November 13, 2025 and Provide Corporate Update

    HORSHAM, Penn., Nov. 05, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report third quarter 2025 financial results on Thursday, November 13, 2025 after the market close. STRATA management will subsequently host a conference call at 4:30 p.m. ET on Thursday, November 13, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, in

    11/5/25 8:00:00 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    Tivic Reports Second Quarter 2025 Financial Results

    Company advances its TLR5 agonist program and prepares to report VNS clinical data Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced financial results for the second quarter and six months ended June 30, 2025. "We have established a strong foundation for Tivic's strategic transformation with our expansion into biopharmaceuticals, making us unique in treating disease by addressing both the body's biochemical and bioelectronic systems," stated Tivic CEO Jennifer Ernst. "To maximize our focus on the compelling, late-stage clinical pipeline, we have increasingly shifted resources away from consumer healthtech and are now planning to exit

    8/14/25 4:00:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care